Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCJ KO CAR-T cells
- Development stage
- Preclinical
- Lead developer
- University of Colorado Anschutz Medical Campus
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
MCJ KO CAR-T cells are an experimental cellular immunotherapy designed to treat B-cell malignancies by enhancing T-cell metabolic fitness. MCJ (also known as DnaJC15) is an endogenous negative regulator of Complex I in the mitochondrial electron transport chain. By knocking out or silencing MCJ, these CAR-T cells exhibit increased mitochondrial respiration, membrane potential, and ATP production. This metabolic modulation leads to superior cytotoxicity, cytokine secretion, and persistence compared to standard CAR-T cells. Preclinical studies, primarily conducted at the University of Colorado Anschutz Medical Campus, have demonstrated enhanced anti-tumor activity against CD19+ B-cell leukemia and melanoma models.
- Other names
- MCJ-deficient CAR-T cellsMCJ-deficient CD8 CAR-T cellsMCJ KO CD19-41BB CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)DNAJC15 (DnaJ heat shock protein family member C15)
Beyond the preview
Go deeper on MCJ KO CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCJ KO CAR-T cells.